S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:ARAV

Aravive (ARAV) Stock Price, News & Analysis

$0.04
0.00 (0.00%)
(As of 02/29/2024 ET)
Today's Range
$0.04
$0.04
50-Day Range
$0.04
$0.13
52-Week Range
$0.04
$2.46
Volume
N/A
Average Volume
N/A
Market Capitalization
$2.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Aravive MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
32,319.0% Upside
$13.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.54 out of 5 stars


ARAV stock logo

About Aravive Stock (NASDAQ:ARAV)

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

ARAV Stock Price History

ARAV Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Why Is Nuvve (NVVE) Stock Down 31% Today?
Why Is Aravive (ARAV) Stock Down 52% Today?
Aravive, Inc. to Delist from The Nasdaq Stock Market
Aravive Stock (NASDAQ:ARAV), Short Interest Report
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Houston is building it. Why won't they come?
Aravive Inc ARAV
Cantor Fitzgerald Downgrades Aravive
William Blair Downgrades Aravive (ARAV)
H.C. Wainwright downgrades Aravive (ARAV) to a Hold
Why Is Aravive Stock Sinking Today?
See More Headlines
Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2021
Today
3/02/2024
Next Earnings (Estimated)
3/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARAV
Fax
N/A
Employees
23
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$18.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+32,319.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-76,320,000.00
Net Margins
-569.65%
Pretax Margin
-569.65%

Debt

Sales & Book Value

Annual Sales
$9.14 million
Book Value
$0.18 per share

Miscellaneous

Free Float
29,131,000
Market Cap
$2.95 million
Optionable
Optionable
Beta
2.11
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Fredric N. Eshelman Pharm.D. (Age 75)
    Executive Chairman
    Comp: $95k
  • Dr. Jeffrey L. Cleland Ph.D. (Age 59)
    Co-Founder
    Comp: $669.98k
  • Dr. Joshua Aaron Silverman Ph.D.
    Co-Founder
  • Mr. Marek Ciszewski J.D.
    Vice President of Investor Relations














ARAV Stock Analysis - Frequently Asked Questions

Should I buy or sell Aravive stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ARAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARAV, but not buy additional shares or sell existing shares.
View ARAV analyst ratings
or view top-rated stocks.

What is Aravive's stock price target for 2024?

4 analysts have issued 12 month price targets for Aravive's stock. Their ARAV share price targets range from $9.00 to $18.00. On average, they expect the company's stock price to reach $13.00 in the next year. This suggests a possible upside of 32,319.0% from the stock's current price.
View analysts price targets for ARAV
or view top-rated stocks among Wall Street analysts.

How have ARAV shares performed in 2024?

Aravive's stock was trading at $0.1237 on January 1st, 2024. Since then, ARAV shares have decreased by 67.6% and is now trading at $0.0401.
View the best growth stocks for 2024 here
.

When is Aravive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our ARAV earnings forecast
.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) announced its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.07. The company had revenue of $2.41 million for the quarter, compared to analysts' expectations of $2.36 million.

What other stocks do shareholders of Aravive own?
Who are Aravive's major shareholders?

Aravive's stock is owned by many different institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (2.69%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amato Giaccia and Gail Frances Mcintyre.
View institutional ownership trends
.

How do I buy shares of Aravive?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARAV) was last updated on 3/2/2024 by MarketBeat.com Staff